Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
about
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis.IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insightsChemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatmeHeparanase augments insulin receptor signaling in breast carcinoma.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesTargeting the Breast Cancer Kinome.Targeted Therapies Against Growth Factor Signaling in Breast Cancer.A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK ExpressionMacrophages and Fibroblasts, Key Players in Cancer ChemoresistanceMolecular Signatures of the Insulin-like Growth Factor 1-mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers
P2860
Q30313824-6A423123-7168-4502-B9CC-073729E3A719Q33436873-6A09DFDC-70CE-49C7-B3BE-7EBE9BC73533Q37615933-ABF25397-FDB4-43CB-9D54-857A46F89E29Q37660216-7D18FAA7-D9A2-4C5F-975F-E53F614C7F1CQ37705915-FF2D38B4-065A-42E1-A676-17EE48923DA0Q37746011-A2B9E1B9-363B-4D56-A339-2DE10047A72EQ38641329-CEB871AA-F1A1-4C67-8E3D-3F7BE927D60BQ38836110-26CECCFB-1B0F-4841-B07E-23BF9504106CQ47559665-599C398D-F449-4E2C-AF25-BC83607BCE10Q47572918-2B80F7FD-4580-4EB9-93D3-252A21C87C3FQ49361356-CE4FA66B-D05D-44CA-8ED2-E527E81BA266Q49723815-06FF823D-6C41-41E2-97CE-61BA70BE55EAQ56968081-48C6A761-B733-4916-B5B8-E5238D3797D3Q57816590-01505E4A-755E-4783-AFC0-D99867ADEED0Q58776408-157DF76E-6E34-4B6A-93AA-156607502B0B
P2860
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical and Translational Res ...... rogressed on Endocrine Therapy
@en
type
label
Clinical and Translational Res ...... rogressed on Endocrine Therapy
@en
prefLabel
Clinical and Translational Res ...... rogressed on Endocrine Therapy
@en
P2093
P2860
P1476
Clinical and Translational Res ...... rogressed on Endocrine Therapy
@en
P2093
Amelie Forest
Denise A Yardley
Dmitri Grebennik
Donald W Northfelt
Ellen Chuang
Gary N Schwartz
Hagop Youssoufian
Jan Cosaert
Joseph A Sparano
Paul Haluska
P2860
P304
P356
10.1158/1078-0432.CCR-15-0588
P407
P577
2015-08-31T00:00:00Z